Patents by Inventor Erik Depla

Erik Depla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11161916
    Abstract: Bispecifc binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: November 2, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gschwind, Rene Georg Ott, Joachim Boucneau, Marie-Ange Buyse, Erik Depla
  • Patent number: 11155607
    Abstract: The present invention relates to polypeptides comprising an immunoglobulin variable domain, binding with high affinity to serum albumin for increasing the half-life of therapeutic agents and compositions, in particular for therapeutic agents comprising multispecific immunoglobulin variable domains. Also provided herein are methods for the production of polypeptides comprising serum albumin binding immunoglobulin variable domains of the present invention.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: October 26, 2021
    Assignee: VIB VZW
    Inventors: Gholamreza Hassanzadeh Ghassabeh, Steve Schoonooghe, Erik Depla
  • Patent number: 11149086
    Abstract: The present invention relates to immunoglobulins that specifically bind Kv1.3 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Kv1.3.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: October 19, 2021
    Assignee: Ablynx N.V.
    Inventors: Diane Van Hoorick, Erik Depla, Frank Kamiel Delphina Verdonck, Veerle Delanote, Daniel Janssen, Francis Descamps, Mark Edward Labadia, Ann Mikhail, Alisa K. Waterman
  • Patent number: 11028151
    Abstract: Amino acid sequences are provided that are directed against/and or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an improved stability, less immunogenicity and/or improved affinity and/or avidity for protein F of hRSV. The invention also relates to the uses of such amino acid sequences, polypeptides, compounds or constructs for prophylactic and/or therapeutic purposes.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: June 8, 2021
    Assignee: Ablynx N.V.
    Inventors: Erik Depla, Catelijne Stortelers, Stephanie Staelens
  • Patent number: 11007146
    Abstract: The present invention relates to methods for the preparation of an aerosol. More specifically the present invention provides methods for the preparation of an aerosol of immunoglobulin single variable domains wherein the amount of aggregate formation is significantly reduced. The invention further provides aerosols prepared by the methods of the invention, as well as compositions for use in the methods of the invention. The invention further relates to methods for the preparations of such compositions, to containers, kits and aerosol delivery systems comprising such compositions and to uses of the same.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: May 18, 2021
    Assignee: Ablynx N.V.
    Inventors: Erik Depla, Mauro Sergi, Peter Casteels
  • Publication number: 20210024631
    Abstract: The present invention relates, in part, to Fc-based chimeric protein complexes and their use as therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Fc-based chimeric protein complexes and their use in the treatment of various diseases.
    Type: Application
    Filed: March 28, 2019
    Publication date: January 28, 2021
    Inventors: Nikolai KLEY, Erik DEPLA, Lennart ZABEAU, Jan TAVERNIER
  • Publication number: 20210024637
    Abstract: The present invention relates, in part, to agents that bind Clec9A and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.
    Type: Application
    Filed: August 8, 2018
    Publication date: January 28, 2021
    Inventors: Nikolai KLEY, Jan TAVERNIER, Lennart ZABEAU, Erik DEPLA
  • Publication number: 20200407448
    Abstract: The present invention relates, in part, to agents that bind PD-1 or PD-L1 and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the PD-1 or PD-L1 binding agents and their use in the treatment of various diseases.
    Type: Application
    Filed: August 8, 2018
    Publication date: December 31, 2020
    Inventors: Nikolai KLEY, Jan TAVERNIER, Lennart ZABEAU, Erik DEPLA
  • Publication number: 20200308244
    Abstract: The present invention relates, in part, to chimeric proteins or chimeric protein complexes, such as Fc-based chimeric protein complexes, comprising interferon alpha 1, or a variant thereof, and their use as therapeutic agents.
    Type: Application
    Filed: March 27, 2020
    Publication date: October 1, 2020
    Applicant: Orionis Biosciences BV
    Inventors: Nikolai KLEY, Erik DEPLA, Lennart ZABEAU, Jan TAVERNIER
  • Publication number: 20200255504
    Abstract: The present invention relates to polypeptides comprising an immunoglobulin variable domain, binding with high affinity to serum albumin for increasing the half-life of therapeutic agents and compositions, in particular for therapeutic agents comprising multispecific immunoglobulin variable domains. Also provided herein are methods for the production of polypeptides comprising serum albumin binding immunoglobulin variable domains of the present invention.
    Type: Application
    Filed: July 17, 2018
    Publication date: August 13, 2020
    Inventors: Gholamreza Hassanzadeh Ghassabeh, Steve Schoonooghe, Erik Depla
  • Publication number: 20200231674
    Abstract: The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.
    Type: Application
    Filed: August 8, 2018
    Publication date: July 23, 2020
    Inventors: Nikolai KLEY, Jan TAVERNIER, Lennart ZABEAU, Erik DEPLA
  • Publication number: 20200207845
    Abstract: Ang2-binding molecules, preferably Ang2-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with Ang2-mediated effects on angiogenesis. Nucleic acids encoding Ang2-binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 2, 2020
    Inventors: Rene Georg Ott, Eric Borges, Andreas Gschwind, Joachim Boucneau, Marie-Ange Buyse, Erik Depla, Pascal Merchiers, Frederik Stevenaert
  • Publication number: 20200123233
    Abstract: The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: August 1, 2019
    Publication date: April 23, 2020
    Applicant: Ablynx N.V.
    Inventors: Catelijne Stortelers, Peter Vanlandschoot, Erik Depla, Jose Melero
  • Patent number: 10561805
    Abstract: Methods are provided for the treatment of RSV infections in young children. More specifically, methods are provided wherein polypeptides that bind F protein of hRSV and that neutralize RSV infection are administered to the lungs of young children at specific dose regimens.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: February 18, 2020
    Assignees: ABLYNX N.V., VECTURA GMBH
    Inventors: Koen Allosery, Erik Depla, Martin Huber, Tobias Kolb, Bernhard Müllinger, Massimiliano Germani, Juliane Schick, Maria-Laura Sargentini
  • Patent number: 10550174
    Abstract: The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: February 4, 2020
    Assignee: Ablynx N.V.
    Inventors: Catelijne Stortelers, Peter Vanlandschoot, Erik Depla, Jose Melero
  • Publication number: 20200010569
    Abstract: Bispecific binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.
    Type: Application
    Filed: July 18, 2019
    Publication date: January 9, 2020
    Inventors: Andreas GSCHWIND, Rene Georg OTT, Joachim BOUCNEAU, Marie-Ange BUYSE, Erik DEPLA
  • Patent number: 10512739
    Abstract: An inhalation device, assembly or system can include a kit and a pharmaceutical composition. The device can be adapted for administering therapeutic aerosols to pediatric patients, including neonates, infants or toddlers. The device can further include a vibrating mesh aerosol generator that can be insertable into a flow channel of the inhalation device through a lateral opening, and a valved face mask. The device can be connectable to a gas source through which a gas, such as oxygen, can be received into the flow channel at a low flow rate.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: December 24, 2019
    Assignees: VECTURA GMBH, ABLYNX N.V.
    Inventors: Koen Allosery, Martin Huber, Tobias Kolb, Bernhard Müllinger, Juliane Schick, Erik Depla
  • Publication number: 20190322753
    Abstract: The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.
    Type: Application
    Filed: July 9, 2019
    Publication date: October 24, 2019
    Inventors: Sanjaya Singh, Alisa K. Waterman, Erik Depla, Toon Laeremans, Diane Van Hoorick, Cedric Jozef Néotère Ververken
  • Patent number: 10414828
    Abstract: Bispecific binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: September 17, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gschwind, Rene Georg Ott, Joachim Boucneau, Marie-Ange Buyse, Erik Depla
  • Patent number: 10407492
    Abstract: The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: September 10, 2019
    Assignee: Ablynx N.V.
    Inventors: Catelijne Stortelers, Peter Vanlandschoot, Erik Depla, Jose Melero